Psoriasis
Conditions
Keywords
dose response; PASI 75 response endpoint; subjects with moderate to severe chronic plaque psoriasis
Brief summary
The purpose of this study is to determine the effectiveness and safety, over 12 weeks, of 3 dosing regimens of CP-690,550 for the treatment of adults with moderate to severe chronic plaque psoriasis.
Interventions
DRUGCP-690,550
tablets, 2 mg BID for 12 weeks
DRUGPlacebo
tablets, BID for 12 weeks
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have been diagnosed with plaque psoriasis for at least 6 months. * Have plaque psoriasis covering at least 15% of their total body. * Be a candidate for phototherapy or systemic treatment of psoriasis (either naïve or history of previous treatment). * Be willing and able to comply with scheduled visits, treatment plan and other study procedures.
Exclusion criteria
* Currently have non-plaque forms of psoriasis or drug-induced psoriasis. * Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot discontinue phototherapy. * Subject is participating in another trial using an investigational agent or procedure. * Women who are pregnant or breast-feeding or considering becoming pregnant.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 | Week 12 | Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 2, 4, 8, 14, 16 | Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). |
| Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 2, 4, 8, 12, 14, 16 | Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). |
| Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 2, 4, 8, 12, 14, 16 | Physician global assessment of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the whole body according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. The score of 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe. |
| Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline, Week 2, 4, 8, 12, 14, 16 | Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). |
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Baseline, Week 2, 4, 8, 12, 14, 16 | Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). |
| Percentage of Participants Achieving a 90% Improvement in Psoriasis Area and Severity Index (PASI 90) Score | Week 12 | Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4). |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| CP-690,550 2 mg CP-690,550 tablets equivalent to CP-690,550 2 mg orally twice daily for 12 weeks. | 49 |
| CP-690,550 5 mg CP-690,550 tablets equivalent to CP-690,550 5 mg orally twice daily for 12 weeks. | 49 |
| CP-690,550 15 mg CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 12 weeks. | 49 |
| Placebo Placebo matched to CP-690,550 tablet orally twice daily for 12 weeks. | 50 |
| Total | 197 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 1 | 2 | 3 | 3 |
| Overall Study | Lack of Efficacy | 2 | 3 | 1 | 9 |
| Overall Study | Lost to Follow-up | 4 | 2 | 0 | 1 |
| Overall Study | Other | 1 | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 3 | 4 | 1 | 7 |
Baseline characteristics
| Characteristic | CP-690,550 2 mg | CP-690,550 5 mg | CP-690,550 15 mg | Placebo | Total |
|---|---|---|---|---|---|
| Age, Customized 18 to 44 years | 23 participants | 25 participants | 28 participants | 20 participants | 96 participants |
| Age, Customized 45 to 54 years | 13 participants | 14 participants | 10 participants | 18 participants | 55 participants |
| Age, Customized 54 to 64 years | 9 participants | 9 participants | 6 participants | 10 participants | 34 participants |
| Age, Customized Greater than or equal to 65 years | 4 participants | 1 participants | 5 participants | 2 participants | 12 participants |
| Sex: Female, Male Female | 20 Participants | 20 Participants | 18 Participants | 14 Participants | 72 Participants |
| Sex: Female, Male Male | 29 Participants | 29 Participants | 31 Participants | 36 Participants | 125 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 25 / 49 | 28 / 49 | 30 / 49 | 30 / 50 |
| serious Total, serious adverse events | 2 / 49 | 1 / 49 | 0 / 49 | 0 / 50 |
Outcome results
Primary
Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Time frame: Week 12
Population: Full analysis set (FAS) included all randomized participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values were imputed using last observation carried forward (LOCF).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 2 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 | 25.00 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 | 40.82 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 | 66.67 percentage of participants |
| Placebo | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score at Week 12 | 2.00 percentage of participants |
Secondary
Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Time frame: Baseline, Week 2, 4, 8, 12, 14, 16
Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. No imputation was done. n=participants evaluable for this measure at specified time points for each arm group respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Erythema (n=37, 36, 41, 30) | -0.9 units on a scale | Standard Error 0.22 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Scaling (n=47, 47, 48, 46) | -0.7 units on a scale | Standard Error 0.09 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Induration (n=43, 40, 47, 39) | -1.0 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Scaling (n=47, 47, 48, 46) | -0.6 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Induration (n=43, 40, 47, 39) | -1.0 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: PASI Total Score (n=47, 48, 48, 49) | -4.7 units on a scale | Standard Error 0.81 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Scaling (n=47, 47, 48, 46) | -0.5 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Induration (n=43, 40, 47, 39) | -1.0 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Erythema (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Induration (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Induration (n=38, 37, 37, 33) | -1.1 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: PASI Total Score (n=37, 36, 41, 30) | -9.7 units on a scale | Standard Error 1.57 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Scaling (n=47, 47, 48, 46) | -0.7 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Induration (n=38, 37, 37, 33) | -0.8 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Induration (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Erythema (n=47, 48, 48, 49) | -0.4 units on a scale | Standard Error 0.11 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Scaling (n=47, 48, 48, 49) | -0.4 units on a scale | Standard Error 0.1 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Induration (n=38, 39, 43, 34) | -1.1 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Induration (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Induration (n=37, 36, 41, 30) | -0.8 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Induration (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Scaling (n=37, 36, 41, 30) | -0.9 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Induration (n=37, 36, 41, 30) | -0.9 units on a scale | Standard Error 0.2 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Scaling (n=47, 48, 48, 49) | -0.3 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Erythema (n=47, 47, 48, 46) | -0.7 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Induration (n=37, 36, 41, 30) | -1.1 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Scaling (n=47, 48, 48, 49) | -0.4 units on a scale | Standard Error 0.1 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Erythema (n=47, 47, 48, 46) | -0.9 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Scaling (n=37, 36, 41, 30) | -0.8 units on a scale | Standard Error 0.2 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Erythema (n=47, 47, 48, 46) | -0.9 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Erythema (n=47, 47, 48, 46) | -0.7 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Scaling (n=37, 36, 41, 30) | -0.7 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Erythema (n=43, 40, 47, 39) | -1.0 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Scaling (n=37, 36, 41, 30) | -1.0 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Erythema (n=43, 40, 47, 39) | -1.2 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Erythema (n=38, 39, 43, 34) | -1.3 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: PASI Total Score (n=38, 37, 37, 33) | -10.9 units on a scale | Standard Error 1.58 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Erythema (n=43, 40, 47, 39) | -1.1 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Induration (n=37, 36, 41, 30) | -1.0 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Scaling (n=38, 37, 37, 33) | -1.2 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Erythema (n=43, 40, 47, 39) | -1.1 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Erythema (n=38, 39, 43, 34) | -1.1 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Scaling (n=38, 37, 37, 33) | -0.8 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Induration (n=38, 37, 37, 33) | -1.1 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Erythema (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.2 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Scaling (n=38, 37, 37, 33) | -0.7 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Erythema (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Scaling (n=47, 48, 48, 49) | -0.5 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Erythema (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Scaling (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Erythema (n=38, 37, 37, 33) | -1.1 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: PASI Total Score (n=38, 39, 43, 34) | -12.1 units on a scale | Standard Error 1.59 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Erythema (n=38, 37, 37, 33) | -1.1 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Scaling (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Erythema (n=38, 37, 37, 33) | -1.1 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Erythema (n=37, 36, 41, 30) | -0.9 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: PASI Total Score (n=43, 40, 47, 39) | -10.9 units on a scale | Standard Error 1.41 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Scaling (n=38, 39, 43, 34) | -1.0 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Erythema (n=37, 36, 41, 30) | -0.8 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Erythema (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.11 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Scaling (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Erythema (n=37, 36, 41, 30) | -0.7 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Scaling (n=38, 39, 43, 34) | -1.3 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Induration (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.11 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Scaling (n=43, 40, 47, 39) | -1.1 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Induration (n=47, 48, 48, 49) | -0.5 units on a scale | Standard Error 0.09 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Induration (n=47, 48, 48, 49) | -0.4 units on a scale | Standard Error 0.1 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: PASI Total Score (n=47, 47, 48, 46) | -7.5 units on a scale | Standard Error 1.05 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Scaling (n=43, 40, 47, 39) | -1.0 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Induration (n=47, 48, 48, 49) | -0.3 units on a scale | Standard Error 0.08 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Erythema (n=47, 48, 48, 49) | -0.4 units on a scale | Standard Error 0.1 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Scaling (n=43, 40, 47, 39) | -0.8 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Induration (n=43, 40, 47, 39) | -0.9 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Induration (n=47, 47, 48, 46) | -0.8 units on a scale | Standard Error 0.11 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Induration (n=47, 47, 48, 46) | -0.6 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Scaling (n=43, 40, 47, 39) | -1.0 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Induration (n=47, 47, 48, 46) | -0.8 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Induration (n=47, 47, 48, 46) | -0.6 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Scaling (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: PASI Total Score (n=47, 47, 48, 46) | -8.6 units on a scale | Standard Error 0.93 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Erythema (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Induration (n=43, 40, 47, 39) | -1.1 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Erythema (n=47, 48, 48, 49) | -0.5 units on a scale | Standard Error 0.09 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Induration (n=43, 40, 47, 39) | -1.1 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Erythema (n=37, 36, 41, 30) | -0.5 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Scaling (n=47, 47, 48, 46) | -0.9 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Induration (n=37, 36, 41, 30) | -0.8 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Induration (n=47, 48, 48, 49) | -0.4 units on a scale | Standard Error 0.08 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Induration (n=43, 40, 47, 39) | -1.1 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Erythema (n=38, 39, 43, 34) | -1.3 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Induration (n=37, 36, 41, 30) | -0.4 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Scaling (n=38, 37, 37, 33) | -1.1 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Induration (n=43, 40, 47, 39) | -1.3 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Erythema (n=37, 36, 41, 30) | -1.0 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Scaling (n=47, 47, 48, 46) | -1.0 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Erythema (n=38, 39, 43, 34) | -1.3 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Induration (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Erythema (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: PASI Total Score (n=38, 39, 43, 34) | -13.1 units on a scale | Standard Error 1.05 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Scaling (n=47, 47, 48, 46) | -0.9 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Scaling (n=43, 40, 47, 39) | -1.3 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Erythema (n=38, 39, 43, 34) | -1.5 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Induration (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Scaling (n=37, 36, 41, 30) | -0.9 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Scaling (n=47, 48, 48, 49) | -0.4 units on a scale | Standard Error 0.09 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Induration (n=47, 47, 48, 46) | -0.8 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Induration (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Scaling (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Induration (n=47, 48, 48, 49) | -0.4 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Erythema (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Induration (n=38, 39, 43, 34) | -1.2 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Erythema (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Scaling (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Scaling (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Induration (n=38, 39, 43, 34) | -1.4 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Scaling (n=38, 39, 43, 34) | -1.4 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Induration (n=47, 47, 48, 46) | -0.7 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Induration (n=38, 37, 37, 33) | -0.9 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Erythema (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Induration (n=47, 47, 48, 46) | -0.9 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Scaling (n=38, 39, 43, 34) | -1.4 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Induration (n=38, 37, 37, 33) | -1.1 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Induration (n=47, 48, 48, 49) | -0.5 units on a scale | Standard Error 0.08 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Scaling (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.1 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Erythema (n=38, 37, 37, 33) | -1.0 units on a scale | Standard Error 0.2 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Scaling (n=47, 47, 48, 46) | -0.8 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Erythema (n=47, 47, 48, 46) | -1.0 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Induration (n=37, 36, 41, 30) | -0.6 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Scaling (n=37, 36, 41, 30) | -0.8 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Scaling (n=37, 36, 41, 30) | -0.5 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Erythema (n=47, 47, 48, 46) | -1.0 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Induration (n=38, 37, 37, 33) | -0.8 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Scaling (n=43, 40, 47, 39) | -1.2 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Erythema (n=38, 37, 37, 33) | -1.2 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Erythema (n=47, 47, 48, 46) | -0.8 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: PASI Total Score (n=38, 37, 37, 33) | -11.4 units on a scale | Standard Error 1.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Scaling (n=37, 36, 41, 30) | -1.0 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: PASI Total Score (n=43, 40, 47, 39) | -11.6 units on a scale | Standard Error 1.09 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Erythema (n=47, 47, 48, 46) | -0.9 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Induration (n=37, 36, 41, 30) | -0.6 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Scaling (n=38, 39, 43, 34) | -1.3 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Erythema (n=47, 48, 48, 49) | -0.7 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Erythema (n=43, 40, 47, 39) | -1.3 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: PASI Total Score (n=37, 36, 41, 30) | -9.3 units on a scale | Standard Error 1.09 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Induration (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Scaling (n=43, 40, 47, 39) | -1.4 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Erythema (n=43, 40, 47, 39) | -1.2 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: PASI Total Score (n=47, 48, 48, 49) | -4.7 units on a scale | Standard Error 0.62 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Erythema (n=37, 36, 41, 30) | -0.7 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Scaling (n=38, 37, 37, 33) | -1.2 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Scaling (n=43, 40, 47, 39) | -1.2 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Erythema (n=43, 40, 47, 39) | -1.2 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Scaling (n=38, 39, 43, 34) | -1.4 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Induration (n=47, 47, 48, 46) | -0.8 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Erythema (n=37, 36, 41, 30) | -0.6 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Erythema (n=43, 40, 47, 39) | -1.4 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Erythema (n=43, 40, 47, 39) | -1.8 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Induration (n=37, 36, 41, 30) | -1.3 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Induration (n=37, 36, 41, 30) | -1.2 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Induration (n=37, 36, 41, 30) | -1.1 units on a scale | Standard Error 0.19 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Induration (n=37, 36, 41, 30) | -1.4 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Erythema (n=47, 48, 48, 49) | -1.0 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Erythema (n=47, 48, 48, 49) | -0.8 units on a scale | Standard Error 0.1 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Erythema (n=47, 48, 48, 49) | -0.8 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Erythema (n=47, 48, 48, 49) | -0.8 units on a scale | Standard Error 0.11 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Erythema (n=47, 47, 48, 46) | -1.4 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Erythema (n=47, 47, 48, 46) | -1.3 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Erythema (n=47, 47, 48, 46) | -1.3 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Erythema (n=47, 47, 48, 46) | -1.3 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Erythema (n=43, 40, 47, 39) | -1.7 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Erythema (n=43, 40, 47, 39) | -1.7 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Erythema (n=43, 40, 47, 39) | -1.7 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Erythema (n=38, 39, 43, 34) | -2.0 units on a scale | Standard Error 0.19 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Erythema (n=38, 39, 43, 34) | -1.8 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Erythema (n=38, 39, 43, 34) | -1.9 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Erythema (n=38, 39, 43, 34) | -1.9 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Erythema (n=38, 37, 37, 33) | -1.5 units on a scale | Standard Error 0.21 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Erythema (n=38, 37, 37, 33) | -1.5 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Erythema (n=38, 37, 37, 33) | -1.6 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Erythema (n=38, 37, 37, 33) | -1.6 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Erythema (n=37, 36, 41, 30) | -1.3 units on a scale | Standard Error 0.21 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Erythema (n=37, 36, 41, 30) | -1.0 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Erythema (n=37, 36, 41, 30) | -1.1 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Erythema (n=37, 36, 41, 30) | -1.3 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Induration (n=47, 48, 48, 49) | -0.8 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Induration (n=47, 48, 48, 49) | -0.8 units on a scale | Standard Error 0.11 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Induration (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.11 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Induration (n=47, 48, 48, 49) | -0.7 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Induration (n=47, 47, 48, 46) | -1.3 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Induration (n=47, 47, 48, 46) | -1.3 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Induration (n=47, 47, 48, 46) | -1.2 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Induration (n=47, 47, 48, 46) | -1.2 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Induration (n=43, 40, 47, 39) | -1.5 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Induration (n=43, 40, 47, 39) | -1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Induration (n=43, 40, 47, 39) | -1.5 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Induration (n=43, 40, 47, 39) | -1.6 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Induration (n=38, 39, 43, 34) | -1.7 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Induration (n=38, 37, 37, 33) | -1.4 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Induration (n=38, 37, 37, 33) | -1.4 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Induration (n=38, 39, 43, 34) | -1.6 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Induration (n=38, 39, 43, 34) | -1.8 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Induration (n=38, 39, 43, 34) | -1.7 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Induration (n=38, 37, 37, 33) | -1.5 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Induration (n=38, 37, 37, 33) | -1.4 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Scaling (n=47, 48, 48, 49) | -0.9 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Scaling (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.1 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Scaling (n=47, 48, 48, 49) | -0.7 units on a scale | Standard Error 0.11 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Scaling (n=47, 48, 48, 49) | -0.6 units on a scale | Standard Error 0.11 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Scaling (n=47, 47, 48, 46) | -1.4 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Scaling (n=47, 47, 48, 46) | -1.0 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Scaling (n=47, 47, 48, 46) | -1.1 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Scaling (n=47, 47, 48, 46) | -0.9 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Scaling (n=43, 40, 47, 39) | -1.6 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Scaling (n=43, 40, 47, 39) | -1.3 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Scaling (n=43, 40, 47, 39) | -1.5 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Scaling (n=43, 40, 47, 39) | -1.4 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Scaling (n=38, 39, 43, 34) | -1.8 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Scaling (n=38, 39, 43, 34) | -1.5 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Scaling (n=38, 39, 43, 34) | -1.8 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Scaling (n=38, 39, 43, 34) | -1.7 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Scaling (n=38, 37, 37, 33) | -1.4 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Scaling (n=38, 37, 37, 33) | -1.3 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Scaling (n=38, 37, 37, 33) | -1.4 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Scaling (n=38, 37, 37, 33) | -1.4 units on a scale | Standard Error 0.19 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Scaling (n=37, 36, 41, 30) | -1.4 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Scaling (n=37, 36, 41, 30) | -1.0 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Scaling (n=37, 36, 41, 30) | -1.2 units on a scale | Standard Error 0.19 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Scaling (n=37, 36, 41, 30) | -1.2 units on a scale | Standard Error 0.19 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: PASI Total Score (n=47, 48, 48, 49) | -7.3 units on a scale | Standard Error 0.86 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: PASI Total Score (n=47, 47, 48, 46) | -12.2 units on a scale | Standard Error 1.18 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: PASI Total Score (n=43, 40, 47, 39) | -15.8 units on a scale | Standard Error 1.38 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: PASI Total Score (n=38, 39, 43, 34) | -17.9 units on a scale | Standard Error 1.59 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: PASI Total Score (n=38, 37, 37, 33) | -16.5 units on a scale | Standard Error 1.95 |
| CP-690,550 15 mg | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: PASI Total Score (n=37, 36, 41, 30) | -14.0 units on a scale | Standard Error 1.77 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: PASI Total Score (n=47, 48, 48, 49) | -0.8 units on a scale | Standard Error 0.69 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Scaling (n=43, 40, 47, 39) | -0.4 units on a scale | Standard Error 0.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Induration (n=47, 48, 48, 49) | -0.3 units on a scale | Standard Error 0.07 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Induration (n=47, 48, 48, 49) | -0.1 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Induration (n=43, 40, 47, 39) | -0.5 units on a scale | Standard Error 0.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Scaling (n=43, 40, 47, 39) | -0.5 units on a scale | Standard Error 0.12 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Induration (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Erythema (n=37, 36, 41, 30) | -0.4 units on a scale | Standard Error 0.13 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Scaling (n=38, 39, 43, 34) | -0.7 units on a scale | Standard Error 0.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Scaling (n=43, 40, 47, 39) | -0.5 units on a scale | Standard Error 0.13 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Erythema (n=37, 36, 41, 30) | -0.6 units on a scale | Standard Error 0.19 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Erythema (n=37, 36, 41, 30) | -0.6 units on a scale | Standard Error 0.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: PASI Total Score (n=38, 37, 37, 33) | -4.4 units on a scale | Standard Error 1.32 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Scaling (n=38, 39, 43, 34) | -0.3 units on a scale | Standard Error 0.2 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Erythema (n=37, 36, 41, 30) | -0.5 units on a scale | Standard Error 0.22 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Erythema (n=38, 37, 37, 33) | -0.4 units on a scale | Standard Error 0.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: PASI Total Score (n=47, 47, 48, 46) | -2.7 units on a scale | Standard Error 0.86 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Scaling (n=38, 39, 43, 34) | -0.6 units on a scale | Standard Error 0.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Erythema (n=38, 37, 37, 33) | -0.5 units on a scale | Standard Error 0.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Erythema (n=38, 37, 37, 33) | -0.7 units on a scale | Standard Error 0.13 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Scaling (n=43, 40, 47, 39) | -0.4 units on a scale | Standard Error 0.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Scaling (n=47, 47, 48, 46) | -0.2 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Scaling (n=38, 39, 43, 34) | -0.6 units on a scale | Standard Error 0.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Erythema (n=38, 37, 37, 33) | -0.6 units on a scale | Standard Error 0.19 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Erythema (n=38, 39, 43, 34) | -0.4 units on a scale | Standard Error 0.12 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Induration (n=37, 36, 41, 30) | -0.3 units on a scale | Standard Error 0.19 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Scaling (n=38, 37, 37, 33) | -0.3 units on a scale | Standard Error 0.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Erythema (n=38, 39, 43, 34) | -0.5 units on a scale | Standard Error 0.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Erythema (n=38, 39, 43, 34) | -0.7 units on a scale | Standard Error 0.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: PASI Total Score (n=43, 40, 47, 39) | -3.7 units on a scale | Standard Error 0.96 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Scaling (n=38, 37, 37, 33) | -0.6 units on a scale | Standard Error 0.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Erythema (n=38, 39, 43, 34) | -0.6 units on a scale | Standard Error 0.2 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Erythema (n=43, 40, 47, 39) | -0.5 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Scaling (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Scaling (n=38, 37, 37, 33) | -0.8 units on a scale | Standard Error 0.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Erythema (n=43, 40, 47, 39) | -0.5 units on a scale | Standard Error 0.12 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Erythema (n=43, 40, 47, 39) | -0.6 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Induration (n=37, 36, 41, 30) | -0.4 units on a scale | Standard Error 0.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Scaling (n=38, 37, 37, 33) | -0.7 units on a scale | Standard Error 0.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Head/Neck Erythema (n=43, 40, 47, 39) | -0.6 units on a scale | Standard Error 0.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Upper Limbs Induration (n=38, 37, 37, 33) | -0.5 units on a scale | Standard Error 0.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Head/Neck Scaling (n=37, 36, 41, 30) | -0.2 units on a scale | Standard Error 0.22 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Erythema (n=47, 47, 48, 46) | -0.4 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Erythema (n=47, 47, 48, 46) | -0.4 units on a scale | Standard Error 0.07 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: PASI Total Score (n=38, 39, 43, 34) | -5.1 units on a scale | Standard Error 1.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Scaling (n=37, 36, 41, 30) | -0.5 units on a scale | Standard Error 0.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Erythema (n=47, 47, 48, 46) | -0.5 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Erythema (n=47, 47, 48, 46) | -0.3 units on a scale | Standard Error 0.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Scaling (n=47, 48, 48, 49) | -0.3 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Induration (n=37, 36, 41, 30) | -0.6 units on a scale | Standard Error 0.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Lower Limbs Induration (n=38, 37, 37, 33) | -0.5 units on a scale | Standard Error 0.13 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Trunk Scaling (n=37, 36, 41, 30) | -0.7 units on a scale | Standard Error 0.19 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Scaling (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.08 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Trunk Induration (n=38, 37, 37, 33) | -0.7 units on a scale | Standard Error 0.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Trunk Induration (n=38, 39, 43, 34) | -0.7 units on a scale | Standard Error 0.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Erythema (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Scaling (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Upper Limbs Induration (n=38, 39, 43, 34) | -0.5 units on a scale | Standard Error 0.16 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Head/Neck Induration (n=38, 39, 43, 34) | -0.4 units on a scale | Standard Error 0.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Trunk Erythema (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 14: Head/Neck Induration (n=38, 37, 37, 33) | -0.5 units on a scale | Standard Error 0.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Lower Limbs Induration (n=43, 40, 47, 39) | -0.5 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Upper Limbs Induration (n=37, 36, 41, 30) | -0.4 units on a scale | Standard Error 0.18 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Scaling (n=47, 47, 48, 46) | -0.4 units on a scale | Standard Error 0.14 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Trunk Induration (n=43, 40, 47, 39) | -0.6 units on a scale | Standard Error 0.13 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: Lower Limbs Scaling (n=37, 36, 41, 30) | -0.6 units on a scale | Standard Error 0.17 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Scaling (n=47, 47, 48, 46) | -0.3 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 8: Upper Limbs Induration (n=43, 40, 47, 39) | -0.3 units on a scale | Standard Error 0.12 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 12: Lower Limbs Induration (n=38, 39, 43, 34) | -0.5 units on a scale | Standard Error 0.11 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Upper Limbs Erythema (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.09 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Induration (n=47, 47, 48, 46) | -0.5 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Trunk Induration (n=47, 47, 48, 46) | -0.4 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Head/Neck Erythema (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.08 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Lower Limbs Scaling (n=47, 47, 48, 46) | -0.4 units on a scale | Standard Error 0.11 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Upper Limbs Induration (n=47, 47, 48, 46) | -0.3 units on a scale | Standard Error 0.1 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 4: Head/Neck Induration (n=47, 47, 48, 46) | -0.3 units on a scale | Standard Error 0.15 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 16: PASI Total Score (n=37, 36, 41, 30) | -5.1 units on a scale | Standard Error 1.42 |
| Placebo | Change From Baseline in Psoriasis Area and Severity Index (PASI) Component Scores and Total Score at Week 2, 4, 8, 12, 14, and 16 | Week 2: Lower Limbs Induration (n=47, 48, 48, 49) | -0.2 units on a scale | Standard Error 0.09 |
Secondary
Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Time frame: Week 2, 4, 8, 12, 14, 16
Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values imputed using LOCF for week 2, 4, 8, 12 and no imputation done for week 14, 16. n=participants evaluable for this measure at specified time points for each arm group respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 2 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 16 (n=37, 36, 41, 30) | 40.54 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 12 (n=48, 49, 48, 50) | 39.58 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 2 (n=47, 48, 48, 49) | 10.64 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 8 (n=48, 49, 48, 50) | 41.67 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 14 (n=38, 37, 37, 33) | 42.11 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 4 (n=48, 49, 48, 50) | 29.17 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 14 (n=38, 37, 37, 33) | 59.46 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 16 (n=37, 36, 41, 30) | 47.22 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 4 (n=48, 49, 48, 50) | 44.90 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 2 (n=47, 48, 48, 49) | 14.58 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 8 (n=48, 49, 48, 50) | 55.10 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 12 (n=48, 49, 48, 50) | 65.31 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 2 (n=47, 48, 48, 49) | 25.00 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 4 (n=48, 49, 48, 50) | 62.50 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 14 (n=38, 37, 37, 33) | 86.49 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 12 (n=48, 49, 48, 50) | 87.50 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 16 (n=37, 36, 41, 30) | 68.29 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 8 (n=48, 49, 48, 50) | 79.17 percentage of participants |
| Placebo | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 16 (n=37, 36, 41, 30) | 23.33 percentage of participants |
| Placebo | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 2 (n=47, 48, 48, 49) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 4 (n=48, 49, 48, 50) | 6.00 percentage of participants |
| Placebo | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 8 (n=48, 49, 48, 50) | 14.00 percentage of participants |
| Placebo | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 14 (n=38, 37, 37, 33) | 24.24 percentage of participants |
| Placebo | Percentage of Participants Achieving a 50% Improvement in Psoriasis Area and Severity Index (PASI 50) Score | Week 12 (n=48, 49, 48, 50) | 20.00 percentage of participants |
Secondary
Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%) - 6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor(head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Time frame: Week 2, 4, 8, 14, 16
Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values imputed using LOCF for week 2, 4, 8 and no imputation done for week 14, 16. n=participants evaluable for this measure at specified time points for each arm group respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 2 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 4 (n=48, 49, 48, 50) | 8.33 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 2 (n=47, 48, 48, 49) | 0.00 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 16 (n=37, 36, 41, 30) | 24.32 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 8 (n=48, 49, 48, 50) | 20.83 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 14 (n=38, 37, 37, 33) | 23.68 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 8 (n=48, 49, 48, 50) | 40.82 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 14 (n=38, 37, 37, 33) | 37.84 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 16 (n=37, 36, 41, 30) | 22.22 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 2 (n=47, 48, 48, 49) | 2.08 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 4 (n=48, 49, 48, 50) | 14.29 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 8 (n=48, 49, 48, 50) | 62.50 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 2 (n=47, 48, 48, 49) | 2.08 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 4 (n=48, 49, 48, 50) | 20.83 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 14 (n=38, 37, 37, 33) | 59.46 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 16 (n=37, 36, 41, 30) | 39.02 percentage of participants |
| Placebo | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 14 (n=38, 37, 37, 33) | 6.06 percentage of participants |
| Placebo | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 4 (n=48, 49, 48, 50) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 2 (n=47, 48, 48, 49) | 0.00 percentage of participants |
| Placebo | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 8 (n=48, 49, 48, 50) | 2.00 percentage of participants |
| Placebo | Percentage of Participants Achieving a 75% Improvement in Psoriasis Area and Severity Index (PASI 75) Score | Week 16 (n=37, 36, 41, 30) | 6.67 percentage of participants |
Secondary
Percentage of Participants Achieving a 90% Improvement in Psoriasis Area and Severity Index (PASI 90) Score
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Time frame: Week 12
Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values imputed using LOCF.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| CP-690,550 2 mg | Percentage of Participants Achieving a 90% Improvement in Psoriasis Area and Severity Index (PASI 90) Score | 14.58 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving a 90% Improvement in Psoriasis Area and Severity Index (PASI 90) Score | 18.37 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving a 90% Improvement in Psoriasis Area and Severity Index (PASI 90) Score | 33.33 percentage of participants |
| Placebo | Percentage of Participants Achieving a 90% Improvement in Psoriasis Area and Severity Index (PASI 90) Score | 0.00 percentage of participants |
Secondary
Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear
Physician global assessment of psoriasis is global consideration of the erythema, induration and scaling across all psoriatic lesions, rated separately over the whole body according to a 5-point severity scale ranged from 0 to 4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. The severity scores are summed and averaged after which the total average is rounded to the nearest whole number score to determine the treatment area overall severity of psoriasis score and category. The score of 0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe.
Time frame: Week 2, 4, 8, 12, 14, 16
Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. Missing values imputed using LOCF for week 2, 4, 8, 12 and no imputation done for week 14, 16. n=participants evaluable for this measure at specified time points for each arm group respectively.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| CP-690,550 2 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 8 (n=49, 49, 48, 50) | 24.49 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 16 (n=37, 37, 41, 30) | 24.32 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 14 (n=38, 37, 37, 33) | 23.68 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 2 (n=48, 48, 48, 49) | 8.33 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 12 (n=49, 49, 48, 50) | 24.49 percentage of participants |
| CP-690,550 2 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 4 (n=49, 49, 48, 50) | 18.37 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 14 (n=38, 37, 37, 33) | 35.14 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 4 (n=49, 49, 48, 50) | 28.57 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 2 (n=48, 48, 48, 49) | 12.50 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 16 (n=37, 37, 41, 30) | 18.92 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 12 (n=49, 49, 48, 50) | 40.82 percentage of participants |
| CP-690,550 5 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 8 (n=49, 49, 48, 50) | 44.90 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 4 (n=49, 49, 48, 50) | 33.33 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 2 (n=48, 48, 48, 49) | 16.67 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 8 (n=49, 49, 48, 50) | 56.25 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 12 (n=49, 49, 48, 50) | 72.92 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 14 (n=38, 37, 37, 33) | 56.76 percentage of participants |
| CP-690,550 15 mg | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 16 (n=37, 37, 41, 30) | 41.46 percentage of participants |
| Placebo | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 16 (n=37, 37, 41, 30) | 10.00 percentage of participants |
| Placebo | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 8 (n=49, 49, 48, 50) | 14.00 percentage of participants |
| Placebo | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 12 (n=49, 49, 48, 50) | 10.00 percentage of participants |
| Placebo | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 2 (n=48, 48, 48, 49) | 4.08 percentage of participants |
| Placebo | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 4 (n=49, 49, 48, 50) | 4.00 percentage of participants |
| Placebo | Percentage of Participants Achieving Physician's Global Assessment (PGA) Score of Clear or Almost Clear | Week 14 (n=38, 37, 37, 33) | 9.09 percentage of participants |
Secondary
Psoriasis Area and Severity Index (PASI) Component Scores and Total Score
Combined assessment of lesion severity and area affected into single score; range=0(no disease)-72(maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated:0(0%)-6(90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4).
Time frame: Baseline, Week 2, 4, 8, 12, 14, 16
Population: FAS included all participants who received at least 1 dose of investigational drug and had at least 1 valid post-baseline efficacy assessment. No imputation was done. n=participants evaluable for this measure at specified time points for each arm group respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Induration (n=43, 40, 47, 39) | 1.0 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Induration(n=48, 49, 48, 50) | 2.5 units on a scale | Standard Error 0.11 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Scaling (n=43, 40, 47, 39) | 1.9 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Induration (n=47, 47, 48, 46) | 1.2 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Induration (n=47, 47, 48, 46) | 1.9 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Induration (n=47, 47, 48, 46) | 1.7 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Induration (n=47, 47, 48, 46) | 2.2 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Induration (n=43, 40, 47, 39) | 1.7 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Induration (n=43, 40, 47, 39) | 1.5 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Induration (n=38, 39, 43, 34) | 1.4 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower limbs induration (n=38, 39, 43, 34) | 1.7 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Induration (n=38, 37, 37, 33) | 1.0 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Induration (n=38, 37, 37, 33) | 1.8 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Induration (n=38, 37, 37, 33) | 1.4 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Induration (n=38, 37, 37, 33) | 1.9 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Induration (n=37, 36, 41, 30) | 1.1 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Induration (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.2 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Induration (n=37, 36, 41, 30) | 1.5 units on a scale | Standard Error 0.2 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Induration (n=37, 36, 41, 30) | 1.9 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Scaling (n=48, 49, 48, 50) | 2.1 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Scaling (n=48, 49, 48, 50) | 2.5 units on a scale | Standard Error 0.1 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Induration (n=47, 47, 48, 46) | 2.1 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Induration(n=47, 48, 48, 49) | 2.5 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Erythema (n=48, 49, 48, 50) | 2.1 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Erythema (n=48, 49, 48, 50) | 2.8 units on a scale | Standard Error 0.09 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Erythema (n=48, 49, 48, 50) | 2.6 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Scaling (n=37, 36, 41, 30) | 1.2 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Scaling (n=38, 37, 37, 33) | 1.9 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Scaling (n=47, 47, 48, 46) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Induration(n=47, 48, 48, 49) | 2.0 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Scaling (n=38, 37, 37, 33) | 1.5 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Scaling (n=38, 37, 37, 33) | 1.8 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Scaling (n=47, 47, 48, 46) | 2.0 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Erythema (n=38, 39, 43, 34) | 1.5 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Scaling (n=38, 37, 37, 33) | 1.2 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower Limbs Scaling (n=38, 39, 43, 34) | 1.8 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Scaling (n=47, 47, 48, 46) | 1.8 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Erythema (n=38, 39, 43, 34) | 1.5 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Scaling (n=38, 39, 43, 34) | 1.3 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Scaling (n=38, 39, 43, 34) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Scaling (n=47, 47, 48, 46) | 2.4 units on a scale | Standard Error 0.11 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Erythema (n=37, 36, 41, 30) | 1.9 units on a scale | Standard Error 0.21 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Scaling (n=38, 39, 43, 34) | 1.0 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Scaling (n=43, 40, 47, 39) | 1.4 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Scaling (n=43, 40, 47, 39) | 1.2 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Induration(n=48, 49, 48, 50) | 2.8 units on a scale | Standard Error 0.09 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Scaling (n=43, 40, 47, 39) | 1.7 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Erythema (n=38, 39, 43, 34) | 1.1 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Erythema (n=43, 40, 47, 39) | 1.8 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Erythema (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.21 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Induration (n=48, 49, 48, 50) | 2.4 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Erythema (n=43, 40, 47, 39) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Erythema (n=43, 40, 47, 39) | 1.6 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Erythema (n=43, 40, 47, 39) | 1.2 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Induration (n=43, 40, 47, 39) | 1.8 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Erythema (n=38, 37, 37, 33) | 1.6 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Erythema (n= 47, 47, 48, 46) | 2.3 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Erythema (n= 47, 47, 48, 46) | 1.8 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Induration (n=38, 39, 43, 34) | 1.0 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Induration (n=47, 48, 48, 49) | 1.4 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Erythema (n=47, 47, 48, 46) | 1.9 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Erythema (n=47, 47, 48, 46) | 1.5 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Induration (n=38, 37, 37, 33) | 1.4 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Induration (n=48, 49, 48, 50) | 2.0 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Erythema (n=47, 48, 48, 49) | 2.6 units on a scale | Standard Error 0.11 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Erythema (n=47, 48, 48, 49) | 2.1 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Erythema (n=37, 36, 41, 30) | 2.2 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Erythema (n=47, 48, 48, 49) | 2.2 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Erythema (n=47, 48, 48, 49) | 1.8 units on a scale | Standard Error 0.15 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Scaling (n=48, 49, 48, 50) | 2.4 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Erythema (n=38, 37, 37, 33) | 2.0 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Erythema (n=48, 49, 48, 50) | 3.0 units on a scale | Standard Error 0.08 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: PASI Total Score | 11.9 units on a scale | Standard Error 1.33 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Scaling (n=48, 49, 48, 50) | 3.1 units on a scale | Standard Error 0.1 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Erythema (n=38, 37, 37, 33) | 1.8 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: PASI Total Score | 10.8 units on a scale | Standard Error 1.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: PASI Total Score | 9.6 units on a scale | Standard Error 1.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Scaling (n=47, 48, 48, 49) | 1.7 units on a scale | Standard Error 0.16 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Erythema (n=38, 37, 37, 33) | 1.2 units on a scale | Standard Error 0.18 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: PASI Total Score | 10.7 units on a scale | Standard Error 1.02 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: PASI Total Score | 14.0 units on a scale | Standard Error 0.98 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Scaling (n=48, 49, 48, 50) | 2.1 units on a scale | Standard Error 0.13 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower Limbs Erythema (n=38, 39, 43, 34) | 1.8 units on a scale | Standard Error 0.17 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: PASI Total Score | 17.0 units on a scale | Standard Error 0.97 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: PASI Total Score | 21.5 units on a scale | Standard Error 0.97 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Scaling (n=47, 48, 48, 49) | 2.1 units on a scale | Standard Error 0.14 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Erythema (n=37, 36, 41, 30) | 1.3 units on a scale | Standard Error 0.2 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Scaling (n=37, 36, 41, 30) | 2.2 units on a scale | Standard Error 0.19 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Scaling (n=37, 36, 41, 30) | 1.7 units on a scale | Standard Error 0.2 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Scaling (n=47, 48, 48, 49) | 2.6 units on a scale | Standard Error 0.12 |
| CP-690,550 2 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Scaling (n=37, 36, 41, 30) | 1.9 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Scaling (n=47, 48, 48, 49) | 2.5 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Erythema (n=38, 37, 37, 33) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Erythema (n=38, 37, 37, 33) | 1.4 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Erythema (n=38, 37, 37, 33) | 1.6 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Erythema (n=37, 36, 41, 30) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Erythema (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Erythema (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Induration (n=43, 40, 47, 39) | 1.3 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Induration (n=38, 39, 43, 34) | 0.5 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Induration (n=38, 37, 37, 33) | 1.2 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Scaling (n=48, 49, 48, 50) | 2.8 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Scaling (n=48, 49, 48, 50) | 2.4 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Scaling (n=48, 49, 48, 50) | 2.9 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Scaling (n=47, 48, 48, 49) | 1.6 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Scaling (n=48, 49, 48, 50) | 2.2 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Scaling (n=47, 48, 48, 49) | 1.8 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Scaling (n=47, 47, 48, 46) | 1.1 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Scaling (n=47, 47, 48, 46) | 1.9 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Scaling (n=47, 47, 48, 46) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Scaling (n=47, 47, 48, 46) | 2.0 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Scaling (n=43, 40, 47, 39) | 0.8 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Scaling (n=43, 40, 47, 39) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Scaling (n=43, 40, 47, 39) | 1.2 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Scaling (n=43, 40, 47, 39) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Scaling (n=38, 39, 43, 34) | 0.8 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Scaling (n=38, 39, 43, 34) | 1.4 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Scaling (n=38, 39, 43, 34) | 1.0 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower Limbs Scaling (n=38, 39, 43, 34) | 1.4 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Scaling (n=38, 37, 37, 33) | 1.1 units on a scale | Standard Error 0.19 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Scaling (n=38, 37, 37, 33) | 1.6 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Scaling (n=38, 37, 37, 33) | 1.3 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Scaling (n=38, 37, 37, 33) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Scaling (n=37, 36, 41, 30) | 1.6 units on a scale | Standard Error 0.2 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Scaling (n=37, 36, 41, 30) | 1.7 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Scaling (n=37, 36, 41, 30) | 1.5 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Scaling (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: PASI Total Score | 21.2 units on a scale | Standard Error 1.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: PASI Total Score | 16.3 units on a scale | Standard Error 1.39 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: PASI Total Score | 12.3 units on a scale | Standard Error 1.46 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: PASI Total Score | 8.1 units on a scale | Standard Error 1.45 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: PASI Total Score | 5.7 units on a scale | Standard Error 0.73 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: PASI Total Score | 7.6 units on a scale | Standard Error 1.06 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: PASI Total Score | 9.1 units on a scale | Standard Error 0.91 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Erythema (n=48, 49, 48, 50) | 2.6 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Erythema (n=48, 49, 48, 50) | 2.9 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Erythema (n=47, 48, 48, 49) | 1.4 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Erythema (n=47, 48, 48, 49) | 2.2 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Erythema (n=47, 48, 48, 49) | 2.0 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Erythema (n=47, 48, 48, 49) | 2.4 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Erythema (n=47, 47, 48, 46) | 1.1 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Erythema (n= 47, 47, 48, 46) | 2.0 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Erythema (n=47, 47, 48, 46) | 1.7 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Erythema (n= 47, 47, 48, 46) | 1.7 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Erythema (n=43, 40, 47, 39) | 1.4 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Erythema (n=43, 40, 47, 39) | 1.3 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Erythema (n=43, 40, 47, 39) | 1.4 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Erythema (n=38, 39, 43, 34) | 0.8 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Erythema (n=38, 39, 43, 34) | 1.3 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Erythema (n=38, 39, 43, 34) | 1.1 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower Limbs Erythema (n=38, 39, 43, 34) | 1.3 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Erythema (n=38, 37, 37, 33) | 1.1 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Erythema (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Induration (n=48, 49, 48, 50) | 1.8 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Induration(n=48, 49, 48, 50) | 2.6 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Induration (n=48, 49, 48, 50) | 2.3 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Induration(n=48, 49, 48, 50) | 2.7 units on a scale | Standard Error 0.1 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Induration (n=47, 47, 48, 46) | 1.7 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Induration(n=47, 48, 48, 49) | 2.1 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Scaling (n=48, 49, 48, 50) | 2.2 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Induration (n=43, 40, 47, 39) | 1.1 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Induration (n=38, 37, 37, 33) | 0.9 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Induration (n=47, 47, 48, 46) | 0.8 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Induration (n=47, 47, 48, 46) | 1.7 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Induration (n=47, 47, 48, 46) | 1.5 units on a scale | Standard Error 0.15 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Induration (n=38, 37, 37, 33) | 1.4 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Induration (n=47, 48, 48, 49) | 1.4 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Induration (n=47, 47, 48, 46) | 1.9 units on a scale | Standard Error 0.13 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Erythema (n=43, 40, 47, 39) | 0.8 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Induration (n=43, 40, 47, 39) | 0.6 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Induration (n=43, 40, 47, 39) | 1.4 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Induration (n=38, 37, 37, 33) | 1.3 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Induration (n=38, 39, 43, 34) | 0.9 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Induration (n=38, 37, 37, 33) | 1.5 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Erythema (n=48, 49, 48, 50) | 2.7 units on a scale | Standard Error 0.11 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Induration (n=37, 36, 41, 30) | 1.2 units on a scale | Standard Error 0.17 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Induration(n=47, 48, 48, 49) | 2.4 units on a scale | Standard Error 0.12 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Induration (n=37, 36, 41, 30) | 1.9 units on a scale | Standard Error 0.16 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Induration (n=37, 36, 41, 30) | 1.6 units on a scale | Standard Error 0.18 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower limbs induration (n=38, 39, 43, 34) | 1.2 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Erythema (n=48, 49, 48, 50) | 2.1 units on a scale | Standard Error 0.14 |
| CP-690,550 5 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Induration (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Induration (n=37, 36, 41, 30) | 1.5 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Induration (n=47, 47, 48, 46) | 2.0 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Erythema (n=48, 49, 48, 50) | 2.4 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower limbs induration (n=38, 39, 43, 34) | 1.0 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower Limbs Scaling (n=38, 39, 43, 34) | 0.9 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Induration (n=38, 37, 37, 33) | 1.1 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Induration(n=47, 48, 48, 49) | 1.9 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Scaling (n=48, 49, 48, 50) | 2.3 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Induration (n=37, 36, 41, 30) | 1.5 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Induration (n=47, 47, 48, 46) | 0.8 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Induration (n=38, 37, 37, 33) | 0.7 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Induration (n=43, 40, 47, 39) | 1.1 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Erythema (n=43, 40, 47, 39) | 1.2 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Induration (n=47, 47, 48, 46) | 1.4 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Induration (n=47, 48, 48, 49) | 1.3 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Induration (n=43, 40, 47, 39) | 0.5 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Induration (n=38, 37, 37, 33) | 1.3 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Induration (n=47, 47, 48, 46) | 1.4 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Induration (n=38, 39, 43, 34) | 0.8 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Erythema (n=48, 49, 48, 50) | 2.8 units on a scale | Standard Error 0.1 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Induration (n=37, 36, 41, 30) | 1.4 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Induration (n=47, 47, 48, 46) | 1.6 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Induration (n=38, 37, 37, 33) | 1.3 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Induration (n=37, 36, 41, 30) | 0.8 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Induration (n=43, 40, 47, 39) | 1.2 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: PASI Total Score | 5.0 units on a scale | Standard Error 0.87 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Scaling (n=37, 36, 41, 30) | 1.7 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Erythema (n=38, 39, 43, 34) | 1.0 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Scaling (n=37, 36, 41, 30) | 1.4 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Scaling (n=47, 48, 48, 49) | 1.9 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Scaling (n=37, 36, 41, 30) | 1.5 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: PASI Total Score | 22.6 units on a scale | Standard Error 1.49 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Scaling (n=48, 49, 48, 50) | 2.0 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Erythema (n=37, 36, 41, 30) | 1.0 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: PASI Total Score | 15.3 units on a scale | Standard Error 1.27 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: PASI Total Score | 10.4 units on a scale | Standard Error 1.13 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Scaling (n=47, 48, 48, 49) | 1.4 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Erythema (n=38, 39, 43, 34) | 0.9 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: PASI Total Score | 6.9 units on a scale | Standard Error 1.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Scaling (n=37, 36, 41, 30) | 1.0 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Scaling (n=48, 49, 48, 50) | 2.7 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Induration (n=48, 49, 48, 50) | 2.6 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: PASI Total Score | 6.7 units on a scale | Standard Error 1.37 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower Limbs Erythema (n=38, 39, 43, 34) | 1.2 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: PASI Total Score | 8.8 units on a scale | Standard Error 1.26 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Erythema (n=38, 37, 37, 33) | 1.4 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Erythema (n=48, 49, 48, 50) | 2.9 units on a scale | Standard Error 0.1 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Scaling (n=48, 49, 48, 50) | 2.5 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Erythema (n=48, 49, 48, 50) | 3.0 units on a scale | Standard Error 0.11 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Erythema (n=38, 37, 37, 33) | 0.9 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Erythema (n=47, 48, 48, 49) | 1.4 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Scaling (n=48, 49, 48, 50) | 2.6 units on a scale | Standard Error 0.09 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Erythema (n=47, 48, 48, 49) | 2.0 units on a scale | Standard Error 0.1 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Erythema (n=38, 37, 37, 33) | 1.3 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Erythema (n=47, 48, 48, 49) | 2.1 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Induration (n=38, 37, 37, 33) | 1.0 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Erythema (n=37, 36, 41, 30) | 1.7 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Erythema (n=47, 48, 48, 49) | 2.3 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Erythema (n=38, 37, 37, 33) | 1.2 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Erythema (n=47, 47, 48, 46) | 1.0 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Induration (n=38, 39, 43, 34) | 0.3 units on a scale | Standard Error 0.1 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Erythema (n=47, 47, 48, 46) | 1.5 units on a scale | Standard Error 0.09 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Induration (n=48, 49, 48, 50) | 2.1 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Erythema (n= 47, 47, 48, 46) | 1.6 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Induration (n=43, 40, 47, 39) | 1.2 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Erythema (n= 47, 47, 48, 46) | 1.8 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Induration(n=47, 48, 48, 49) | 2.1 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Erythema (n=43, 40, 47, 39) | 0.6 units on a scale | Standard Error 0.13 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Erythema (n=43, 40, 47, 39) | 1.1 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Scaling (n=43, 40, 47, 39) | 0.7 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Erythema (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Scaling (n=43, 40, 47, 39) | 1.3 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Induration(n=48, 49, 48, 50) | 2.8 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Scaling (n=43, 40, 47, 39) | 1.0 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Erythema (n=43, 40, 47, 39) | 1.2 units on a scale | Standard Error 0.16 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Scaling (n=43, 40, 47, 39) | 1.3 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Scaling (n=47, 47, 48, 46) | 1.8 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Scaling (n=38, 39, 43, 34) | 0.5 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Scaling (n=38, 39, 43, 34) | 1.1 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Scaling (n=47, 47, 48, 46) | 1.4 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Induration(n=48, 49, 48, 50) | 2.7 units on a scale | Standard Error 0.11 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Scaling (n=38, 39, 43, 34) | 0.7 units on a scale | Standard Error 0.12 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Scaling (n=47, 47, 48, 46) | 1.6 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Erythema (n=37, 36, 41, 30) | 1.7 units on a scale | Standard Error 0.15 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Scaling (n=38, 37, 37, 33) | 0.9 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Scaling (n=38, 37, 37, 33) | 1.3 units on a scale | Standard Error 0.17 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Scaling (n=47, 47, 48, 46) | 0.9 units on a scale | Standard Error 0.14 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Erythema (n=38, 39, 43, 34) | 0.4 units on a scale | Standard Error 0.11 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Scaling (n=38, 37, 37, 33) | 1.1 units on a scale | Standard Error 0.18 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Scaling (n=38, 37, 37, 33) | 1.3 units on a scale | Standard Error 0.2 |
| CP-690,550 15 mg | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Scaling (n=47, 48, 48, 49) | 2.1 units on a scale | Standard Error 0.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Scaling (n=43, 40, 47, 39) | 2.4 units on a scale | Standard Error 0.15 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Scaling (n=37, 36, 41, 30) | 1.7 units on a scale | Standard Error 0.22 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Induration (n=47, 48, 48, 49) | 1.9 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Erythema (n=38, 37, 37, 33) | 2.3 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Scaling (n=38, 37, 37, 33) | 1.7 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Scaling (n=37, 36, 41, 30) | 2.3 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Scaling (n=47, 48, 48, 49) | 2.3 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Erythema (n=47, 47, 48, 46) | 2.1 units on a scale | Standard Error 0.15 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Erythema (n=43, 40, 47, 39) | 2.3 units on a scale | Standard Error 0.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Scaling (n=37, 36, 41, 30) | 2.0 units on a scale | Standard Error 0.2 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Erythema (n=38, 37, 37, 33) | 1.7 units on a scale | Standard Error 0.2 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Erythema (n=38, 39, 43, 34) | 2.3 units on a scale | Standard Error 0.15 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Scaling (n=47, 47, 48, 46) | 1.8 units on a scale | Standard Error 0.16 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Scaling (n=37, 36, 41, 30) | 2.4 units on a scale | Standard Error 0.19 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Scaling (n=48, 49, 48, 50) | 2.4 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Erythema (n=38, 39, 43, 34) | 2.4 units on a scale | Standard Error 0.17 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Erythema (n=47, 47, 48, 46) | 2.5 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: PASI Total Score | 21.5 units on a scale | Standard Error 1.01 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Induration (n=43, 40, 47, 39) | 2.2 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Scaling (n=38, 39, 43, 34) | 1.6 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Scaling (n=47, 47, 48, 46) | 2.4 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: PASI Total Score | 20.4 units on a scale | Standard Error 1.23 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Scaling (n=47, 48, 48, 49) | 1.9 units on a scale | Standard Error 0.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Induration(n=48, 49, 48, 50) | 2.7 units on a scale | Standard Error 0.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Erythema (n= 47, 47, 48, 46) | 2.5 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: PASI Total Score | 19.1 units on a scale | Standard Error 1.5 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Erythema (n=37, 36, 41, 30) | 2.3 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Induration(n=48, 49, 48, 50) | 2.5 units on a scale | Standard Error 0.1 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Erythema (n= 47, 47, 48, 46) | 2.8 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: PASI Total Score | 17.3 units on a scale | Standard Error 1.31 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Scaling (n=48, 49, 48, 50) | 2.9 units on a scale | Standard Error 0.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Erythema (n=38, 37, 37, 33) | 2.6 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Scaling (n=47, 48, 48, 49) | 2.7 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: PASI Total Score | 15.8 units on a scale | Standard Error 1.3 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Scaling (n=38, 37, 37, 33) | 2.1 units on a scale | Standard Error 0.17 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Erythema (n=43, 40, 47, 39) | 1.8 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Erythema (n=37, 36, 41, 30) | 2.3 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: PASI Total Score | 16.1 units on a scale | Standard Error 1.39 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Scaling (n=48, 49, 48, 50) | 2.6 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Induration (n=48, 49, 48, 50) | 2.0 units on a scale | Standard Error 0.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Erythema (n=38, 39, 43, 34) | 1.7 units on a scale | Standard Error 0.19 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Erythema (n=43, 40, 47, 39) | 2.3 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Scaling (n=43, 40, 47, 39) | 1.6 units on a scale | Standard Error 0.16 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Erythema (n=48, 49, 48, 50) | 2.8 units on a scale | Standard Error 0.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Scaling (n=38, 39, 43, 34) | 1.9 units on a scale | Standard Error 0.19 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Trunk Induration (n=48, 49, 48, 50) | 2.7 units on a scale | Standard Error 0.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Scaling (n=47, 47, 48, 46) | 2.3 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Lower Limbs Erythema (n=48, 49, 48, 50) | 3.1 units on a scale | Standard Error 0.08 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Scaling (n=48, 49, 48, 50) | 2.6 units on a scale | Standard Error 0.1 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Lower Limbs Erythema (n=43, 40, 47, 39) | 2.5 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Scaling (n=43, 40, 47, 39) | 2.2 units on a scale | Standard Error 0.15 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Head/Neck Erythema (n=47, 48, 48, 49) | 2.2 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Scaling (n=38, 39, 43, 34) | 2.0 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Erythema (n=38, 37, 37, 33) | 2.4 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Scaling (n=47, 47, 48, 46) | 2.5 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Erythema (n=47, 48, 48, 49) | 2.7 units on a scale | Standard Error 0.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Upper Limbs Induration (n=38, 37, 37, 33) | 2.0 units on a scale | Standard Error 0.16 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower Limbs Scaling (n=38, 39, 43, 34) | 2.3 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Erythema (n=37, 36, 41, 30) | 1.8 units on a scale | Standard Error 0.22 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Erythema (n=47, 48, 48, 49) | 2.7 units on a scale | Standard Error 0.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Scaling (n=43, 40, 47, 39) | 2.1 units on a scale | Standard Error 0.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Scaling (n=38, 37, 37, 33) | 2.2 units on a scale | Standard Error 0.19 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Scaling (n=38, 37, 37, 33) | 1.8 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Erythema (n=47, 48, 48, 49) | 2.9 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Head/Neck Induration (n=38, 39, 43, 34) | 1.5 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Erythema (n=37, 36, 41, 30) | 2.7 units on a scale | Standard Error 0.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Erythema (n=48, 49, 48, 50) | 2.4 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Head/Neck Induration (n=43, 40, 47, 39) | 1.5 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Upper Limbs Induration (n=43, 40, 47, 39) | 2.2 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 8: Trunk Induration (n=43, 40, 47, 39) | 2.0 units on a scale | Standard Error 0.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Trunk Induration (n=38, 39, 43, 34) | 2.0 units on a scale | Standard Error 0.17 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Upper Limbs Induration(n=47, 48, 48, 49) | 2.4 units on a scale | Standard Error 0.1 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower limbs induration (n=38, 39, 43, 34) | 2.2 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Upper Limbs Erythema (n=48, 49, 48, 50) | 2.9 units on a scale | Standard Error 0.07 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Head/Neck Induration (n=38, 37, 37, 33) | 1.4 units on a scale | Standard Error 0.17 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Upper Limbs Induration (n=38, 37, 37, 33) | 2.1 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Trunk Induration (n=38, 37, 37, 33) | 1.9 units on a scale | Standard Error 0.17 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Trunk Induration (n=47, 47, 48, 46) | 2.4 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 14: Lower Limbs Induration (n=38, 37, 37, 33) | 2.2 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Head/Neck Induration (n=37, 36, 41, 30) | 1.6 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Upper Limbs Induration (n=37, 36, 41, 30) | 2.2 units on a scale | Standard Error 0.15 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Trunk Induration (n=37, 36, 41, 30) | 2.1 units on a scale | Standard Error 0.18 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: Lower Limbs Induration (n=37, 36, 41, 30) | 2.4 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 12: Lower Limbs Erythema (n=38, 39, 43, 34) | 2.6 units on a scale | Standard Error 0.13 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 16: PASI Total Score | 16.4 units on a scale | Standard Error 1.66 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 2: Lower Limbs Induration(n=47, 48, 48, 49) | 2.6 units on a scale | Standard Error 0.09 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Head/Neck Induration (n=47, 47, 48, 46) | 1.7 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Baseline: Head/Neck Scaling (n=48, 49, 48, 50) | 2.2 units on a scale | Standard Error 0.14 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Upper Limbs Induration (n=47, 47, 48, 46) | 2.2 units on a scale | Standard Error 0.12 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Trunk Induration (n=47, 47, 48, 46) | 2.3 units on a scale | Standard Error 0.11 |
| Placebo | Psoriasis Area and Severity Index (PASI) Component Scores and Total Score | Week 4: Lower Limbs Induration (n=47, 47, 48, 46) | 2.3 units on a scale | Standard Error 0.11 |